Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1281MR)

This product GTTS-WQ1281MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1281MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8342MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ4576MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ4835MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ10880MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ4672MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ10388MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ5345MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ14772MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-40
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW